Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACEPHEN vs PEMETREXED DITROMETHAMINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), enzymes involved in folate-dependent purine and pyrimidine synthesis, leading to disruption of DNA synthesis and cell death.
Mild to moderate pain,Fever
FDA-approved: In combination with cisplatin for initial treatment of patients with malignant pleural mesothelioma who are unresectable or not surgical candidates.,FDA-approved: As a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior platinum-based chemotherapy.,FDA-approved: In combination with pembrolizumab and platinum chemotherapy for first-line treatment of metastatic non-squamous NSCLC.,Off-label: Treatment of recurrent or metastatic cervical cancer, breast cancer, bladder cancer, colorectal cancer, and others.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
500 mg/m2 intravenously over 10 minutes every 21 days.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Terminal half-life 3.5 hours (range 2.5-5.0 hours) in patients with normal renal function; prolonged to 5-10 hours in moderate renal impairment. Clinical context: Half-life is dose-independent; clearance correlates with creatinine clearance.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Pemetrexed is primarily excreted unchanged in the urine. It undergoes minimal hepatic metabolism; less than 5% is metabolized by the liver.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Primarily renal excretion: 70-90% of the dose is eliminated unchanged in urine within 24 hours. Fecal excretion accounts for <5%.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
81% bound primarily to albumin; minimal binding to alpha-1-acid glycoprotein.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Vd at steady state = 16.1 L/m² (approximately 0.4 L/kg in adults). Clinical meaning: Indicates distribution into total body water with limited tissue binding; low Vd suggests minimal extravascular distribution.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
Intravenous only; bioavailability is 100% by IV route. Not orally available due to poor absorption and extensive first-pass metabolism.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Cr Cl ≥45 m L/min: 500 mg/m2; Cr Cl 30-44 m L/min: 375 mg/m2; Cr Cl <30 m L/min: not recommended.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
No dose adjustment recommended for Child-Pugh A or B. Child-Pugh C: no data.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Not established; safety and efficacy not determined in pediatric patients.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
No specific dose adjustment; monitor renal function closely due to age-related decline in Cr Cl.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Pemetrexed can cause severe or fatal hypersensitivity reactions, including anaphylaxis. It also causes severe myelosuppression, which may require dose modification or discontinuation. Patients must be pretreated with corticosteroids and vitamin supplementation to reduce toxicity.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Myelosuppression: Dose-dependent, monitor blood counts regularly.,Renal toxicity: Excreted renally; adjust dose in renal impairment (Cr Cl <45 m L/min).,Gastrointestinal toxicity: Nausea, vomiting, diarrhea; may require antiemetics.,Hypersensitivity reactions: Premedicate with corticosteroids.,Folic acid and vitamin B12 deficiency: Supplement to reduce hematologic toxicity.,Third-space fluid accumulation: Consider drainage before treatment.
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
History of severe hypersensitivity reaction to pemetrexed or any excipients.,Concurrent yellow fever vaccine (risk of systemic fatal disease).,Severe renal impairment (Cr Cl <45 m L/min) not meeting criteria for dose adjustment.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
No specific dietary restrictions. However, folic acid supplements and vitamin B12 are required. Avoid folic acid antagonists like methotrexate.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Pemetrexed is a folate analog metabolic inhibitor that is teratogenic in animals. In humans, it is contraindicated in pregnancy due to its mechanism of action interfering with DNA synthesis and cell division. First trimester exposure carries the highest risk of major congenital malformations (e.g., neural tube defects, craniofacial anomalies). Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and potential fetal demise. Use in pregnant women is not recommended unless no safer alternative exists.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
There are no data on the presence of pemetrexed in human milk, its effects on the breastfed infant, or milk production. Due to the potential for serious adverse reactions in nursing infants (e.g., myelosuppression, gastrointestinal toxicity), breastfeeding is not recommended during pemetrexed therapy and for at least one week after the last dose. The M/P ratio is unknown.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
No specific dosing adjustments for pregnancy are established due to lack of data. Physiologic changes in pregnancy (increased renal clearance, expanded plasma volume) may reduce drug exposure, but dose increases are not recommended due to potential fetal toxicity. In animal studies, lower doses produced embryotoxicity. Therefore, dose adjustments should not be made; the drug should be avoided in pregnancy.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Administer folic acid and vitamin B12 supplementation to reduce toxicity. Premedicate with corticosteroids to prevent rash. Monitor renal function; dose adjust for Cr Cl <45 m L/min. Avoid NSAIDs for 2 days before and after dose. Ensure adequate hydration. Do not mix with calcium-containing solutions.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
Take folic acid daily and vitamin B12 injections every 9 weeks as prescribed.,Inform all healthcare providers about your treatment; avoid NSAIDs like ibuprofen or naproxen.,Report new or worsening rash, diarrhea, or mouth sores immediately.,Drink plenty of fluids to stay hydrated.,Avoid receiving live vaccines during treatment.
No interactions on record
"Methotrimeprazine may reduce the gastrointestinal absorption of tromethamine, an alkalinizing agent, leading to decreased systemic exposure and potentially diminished therapeutic efficacy. This interaction is hypothesized to occur via altered gastric pH or motility, though direct evidence is limited. Patients may experience reduced effectiveness of tromethamine in managing acid-base disorders."
"Tromethamine, an alkalinizing agent used to correct metabolic acidosis, can increase gastric pH, which may reduce the absorption of weakly acidic drugs like estrone sulfate. This altered gastrointestinal environment can decrease estrone sulfate bioavailability, potentially compromising its systemic effects for hormone replacement therapy. Clinically, this may lead to reduced efficacy of estrone sulfate, requiring dose adjustments or alternative administration routes."
"Tromethamine, an alkalinizing agent, can increase urinary pH, which enhances the renal excretion of sotalol, a class III antiarrhythmic that is primarily eliminated unchanged by the kidneys. This interaction may lead to reduced serum sotalol concentrations, potentially decreasing its therapeutic efficacy and increasing the risk of arrhythmia recurrence, particularly in patients with renal impairment or those requiring precise antiarrhythmic control."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACEPHEN vs PEMETREXED DITROMETHAMINE, answered by our medical review team.
ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. PEMETREXED DITROMETHAMINE is a Antineoplastic Antifolate that works by Pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), enzymes involved in folate-dependent purine and pyrimidine synthesis, leading to disruption of DNA synthesis and cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACEPHEN and PEMETREXED DITROMETHAMINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. The standard adult dose of PEMETREXED DITROMETHAMINE is: 500 mg/m2 intravenously over 10 minutes every 21 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACEPHEN and PEMETREXED DITROMETHAMINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. PEMETREXED DITROMETHAMINE is classified as Category C. Pemetrexed is a folate analog metabolic inhibitor that is teratogenic in animals. In humans, it is contraindicated in pregnancy due to its mechanism of action interfering with DNA . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.